Abstract
The present study relates to the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analog of Boswellic acid i.e. 3-α-Butyryloxy-β-boswellic acid (BOBA). The cytotoxicity data revealed the differential sensitivity of cancer cell lines towards BOBA which may display its impact against different types of cancers. Considering the inhibitory potential of BOBA, we further sought to understand the target for BOBA deciphering the mechanism of action leading to apoptotic cell death and it was for the first time reported about the triterpenoid ring especially the β-boswellic acid derivative is targeting PI3K pathway. Our data revealed that BOBA treatment provides evidence about the apoptotic nature showing the potential of targeting mitochondria dependent pathways during apoptosis in HL-60 cells. BOBA induced hypo-diploid sub-G1 DNA population in HL-60 cells as was also evident from the pattern of DNA fragmentation and mitochondrial membrane potential (ΛΨm) loss. Morphological analysis under fluorescent and scanning electron microscopy displayed typical features such as cell shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation. These events paralleled with the down-regulation of NF-κB and induced PARP cleavage. Furthermore, it is noteworthy that BOBA also depicted significant growth inhibition in Ehrlich Ascitic Tumour (EAT), Ehrlich Ascitic Carcinoma (EAC) and Sarcoma- 180 tumour models. Taken together, BOBA treatment may represent as potential agent to the currently available anticancer agents in both prophylactic and/or therapeutic applications. Also, our findings may open up a new perspective in the construction of novel anticancer agents based on boswellic acids that will facilitate the development of these agents for anticancer therapeutics.
Keywords: DNA repair, Apoptosis, Cancer, Natural Products, Drug, Signaling, PI3K, Boswellia serrata.
Anti-Cancer Agents in Medicinal Chemistry
Title:NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Volume: 13 Issue: 5
Author(s): Yasrib Qurishi, Abid Hamid, Parduman R. Sharma, Zahoor A. Wani, Dilip M. Mondhe, Shashank K. Singh, Mohmmad A. Zargar, Samar S. Andotra, Bhahwal A. Shah, Subhash C. Taneja and Ajit K. Saxena
Affiliation:
Keywords: DNA repair, Apoptosis, Cancer, Natural Products, Drug, Signaling, PI3K, Boswellia serrata.
Abstract: The present study relates to the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analog of Boswellic acid i.e. 3-α-Butyryloxy-β-boswellic acid (BOBA). The cytotoxicity data revealed the differential sensitivity of cancer cell lines towards BOBA which may display its impact against different types of cancers. Considering the inhibitory potential of BOBA, we further sought to understand the target for BOBA deciphering the mechanism of action leading to apoptotic cell death and it was for the first time reported about the triterpenoid ring especially the β-boswellic acid derivative is targeting PI3K pathway. Our data revealed that BOBA treatment provides evidence about the apoptotic nature showing the potential of targeting mitochondria dependent pathways during apoptosis in HL-60 cells. BOBA induced hypo-diploid sub-G1 DNA population in HL-60 cells as was also evident from the pattern of DNA fragmentation and mitochondrial membrane potential (ΛΨm) loss. Morphological analysis under fluorescent and scanning electron microscopy displayed typical features such as cell shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation. These events paralleled with the down-regulation of NF-κB and induced PARP cleavage. Furthermore, it is noteworthy that BOBA also depicted significant growth inhibition in Ehrlich Ascitic Tumour (EAT), Ehrlich Ascitic Carcinoma (EAC) and Sarcoma- 180 tumour models. Taken together, BOBA treatment may represent as potential agent to the currently available anticancer agents in both prophylactic and/or therapeutic applications. Also, our findings may open up a new perspective in the construction of novel anticancer agents based on boswellic acids that will facilitate the development of these agents for anticancer therapeutics.
Export Options
About this article
Cite this article as:
Qurishi Yasrib, Hamid Abid, Sharma Parduman R., Wani Zahoor A., Mondhe Dilip M., Singh Shashank K., Zargar Mohmmad A., Andotra Samar S., Shah Bhahwal A., Taneja Subhash C. and Saxena Ajit K., NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1871520611313050012
DOI https://dx.doi.org/10.2174/1871520611313050012 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Coumarins as Inhibitors of HIV Reverse Transcriptase
Current HIV Research Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor
Reviews on Recent Clinical Trials Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Phytoecdysteroids - From Isolation to Their Effects on Humans
Current Medicinal Chemistry Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug
Anti-Cancer Agents in Medicinal Chemistry Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry